NCT06203444View on ClinicalTrials.gov

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Lactation
Interventions
DRUG

Tenapanor

The study drug will be administered in dose of 50 mg bid

Trial Locations (2)

53704

Fortrea Clinical Research Unit, Madison

73112

DDSI, Oklahoma City

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY